A Few Simple Snarky Rules to Make Life Better
Jamie Raskin's Low Opinion of Women
Thank You, GOD!
A Quick Bible Study Vol. 306: ‘Fear Not' Old Testament – Part 2
The War on Warring
TrumpRX Triggers TDS in Elizabeth Warren
Texas Democrat Goes Viral After Pitting Whites Against Minorities
U.S. Secret Service Seized 3 Card Skimmers in Alabama, Stopping $3.1M in Fraud
Jasmine Crockett Finally Added Some Policy to Her Website and it Was a...
No Sanctuary in the Sanctuary
Chromosomes Matter — and Women’s Sports Prove It
The Economy Will Decide Congress — If Republicans Actually Talk About It
The Real United States of America
These Athletes Are Getting Paid to Shame Their Own Country at the Olympics
WaPo CEO Resigns Days After Laying Off 300 Employees
OPINION

Cheap Oil & Top Line Growth

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.

Once again, crude oil takes it on the chin as the downside slide continues to pick up steam. A month ago, the uptrend-line that marked the rebound from February’s swoon was violated; and now, West Texas Intermediate (WTI) is approaching a critical support point.

Advertisement

After crude began to tumble on Monday, equities surged to the upside for a split second but that move was short-lived.  The good news is that stocks worked back toward the flat line into the closing bell, but the bad news is that crude-equity correlation could be a major drag on stocks.

There is a chance it could be a non-event by Friday, but it’s important $39.00 holds as a very important support point.

 

Rotation

I wrote about the earnings and guidance disappointments for Utilities and Staples thus far in this earnings season.  Now that it’s clear those safe havens are overpriced, I suspect there will be a greater sense of urgency to rotate elsewhere. 

Monday, it was the NASDAQ composite, which leaped to a 52-week high paced by some big tech names that continue to rebound in Netflix (NFLX), although most of the credit should go to biotechnology. 

IBB

 

Biotechnology is down 26%  since its high last July, but closed on Monday above key resistance; this rally could pick up steam.  One name I like a lot is Biogen (BIIB), which I think could move up more than 100 points.

IBB

 

While the market grapples with free-falling crude and new leadership, don’t forget the jobs report looms large on Friday. 

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement